Biotest (BIO.DE) Stock Price
Biotest Price
Revenue has compounded at 6.1% per year over the past 19 years to 726.20 M EUR. Earnings per share have grown at 1.5% per year over the last 17 years. Biotest's net margin stands at 3.6%, up from -6.5% several years earlier. Biotest currently offers a dividend yield of about 0.13%. The dividend has grown at 2.9% per year over the past 12 years.
Biotest stock price
Biotest business model & stock analysis
Frequently asked questions about Biotest
The business model of Biotest AG revolves around the development, production, and distribution of innovative biotherapeutic products. Biotest AG focuses on the areas of clinical immunology, hematology, and intensive care medicine. The company's primary goal is to provide patients with effective and safe treatments for various diseases and medical conditions. Biotest AG's portfolio includes plasma-derived and monoclonal antibody-based therapies. By leveraging their expertise in biotechnology, Biotest AG aims to contribute to improving patients' quality of life. With a strong dedication to research and development, the company continuously strives to introduce novel and advanced solutions in the field of biotherapeutics.
Biotest AG is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biotest AG in the market are CSL Behring, Grifols, and Octapharma. These companies also operate in the field of plasma protein therapies and pharmaceutical products, competing with Biotest AG in terms of product offerings, global reach, and market share.
Biotest AG is a leading biopharmaceutical company with a rich history and background. Founded in 1946, the company specializes in the development, production, and marketing of immunology and haematology products. Biotest AG has been at the forefront of medical innovation, focusing on therapeutics that cater to patients with severe immune deficiencies and haematological disorders. With a commitment to excellence and a strong research-driven approach, Biotest AG has established itself as a trusted name in the healthcare industry. Today, the company continues to provide life-saving treatments, leveraging its expertise and state-of-the-art facilities to improve patient outcomes around the world.
Biotest AG, a leading biotechnology company, has achieved several significant milestones in its corporate journey. Some noteworthy accomplishments include the successful completion of clinical trials for its innovative therapeutics and the subsequent approval of these products by regulatory authorities. Biotest AG has also secured strategic partnerships and collaborations with renowned pharmaceutical companies, enabling wider distribution and increased market reach for its offerings. Moreover, the company has consistently focused on research and development, resulting in the launch of cutting-edge treatment options that have revolutionized patient care in various therapeutic areas. These achievements testify to Biotest AG's commitment to advancing medical science and improving healthcare outcomes.
Biotest AG is primarily present in several countries and regions. The company has a strong presence in Germany, where its headquarters is located. It also has significant operations in Austria and Switzerland. Furthermore, Biotest AG has expanded its reach to other European countries such as France, Italy, and the United Kingdom. Additionally, the company has a strong presence in the United States, where it has established manufacturing facilities and distribution networks. With a global presence, Biotest AG continues to expand its market presence and deliver high-quality products and services to customers worldwide.
Biotest AG represents values of innovation, quality, and dedication in the field of biotechnology. The company's corporate philosophy revolves around delivering life-saving therapies and diagnostic tools to patients worldwide. Biotest AG is committed to advancing healthcare by developing and producing plasma proteins, blood clotting factors, and immunoglobulins. With a strong focus on research and development, Biotest AG strives to meet the highest standards of safety and efficacy in its products. The company's dedication to improving patient lives and constant pursuit of scientific excellence distinguishes Biotest AG in the biotechnology industry.
7 analysts currently rate the Biotest stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Biotest to generate revenue of 702.32 M EUR and earnings per share of 7.22 EUR.
The Biotest share (BIO.DE) is listed on 9 stock exchanges, including: London (0N6Z.L), SIX (Zürich) (BIOCHF.SW), XETRA (BIO.DE), Frankfurt (BIO.F), München (BIO.MU), Stuttgart (BIO.SG), Düsseldorf (BIO.DU), Berlin (BIO.BE).
The Biotest AG is an international biotechnology company focused on the development, manufacturing, and distribution of biopharmaceutical products as well as reagents and diagnostics. The company operates worldwide with headquarters in Europe and the USA. The business model of Biotest is centered around developing and marketing innovative therapeutics and medical diagnostic solutions. The company serves different business areas such as hematology, immunology, and intensive care medicine. Within these areas, Biotest offers various product lines typically focused on plasma-based therapies. Among other things, the company offers immunoglobulins (antibodies), platelet preparations, coagulation factors, and albumin preparations that can be used in patients with certain blood disorders or immunodeficiencies. Additionally, Biotest also supplies plasma products and diagnostic products to medical facilities and laboratories worldwide. Another important business area is research and development. Through state-of-the-art technology and research methods, the company intensively researches the development of new therapeutic options and diagnostic solutions. The company is particularly committed to sustainable production and the highest possible product quality. Biotest therefore closely collaborates with partners around the world to enable global sourcing of blood plasma and ensure proximity to important production sites. The company relies on innovative manufacturing processes and continuous improvement of working and production conditions. In addition to manufacturing and marketing plasma products and diagnostics, Biotest is also involved in the development of therapy components based on innovative technologies such as nanoparticles, antibodies, or RNA. This usually involves targeted therapy for cancer, blood disorders, and autoimmune diseases. The success of Biotest's business model is reflected in constant growth and increasing demand for the company's products. Biotest is now a global biotechnology company specializing in the production of plasma products and diagnostics, characterized by a high degree of sustainability and innovative technologies. Continuous research and development of new therapy options and close collaboration with global partners are essential to the company's success and its employees. Biotest's goal is to provide patients worldwide with high-quality medications and diagnostic solutions, thereby contributing to enabling people to lead a healthy and fulfilling life.
The expected revenue of Biotest is 702.32 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biotest is 279.47 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biotest is currently 5.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biotest stock.
The price-to-sales ratio (P/S) of Biotest is currently 2.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biotest stock.
The Eulerpool Quality Score for Biotest is 3/10.
The ISIN of Biotest is DE0005227201. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotest is 522720. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotest is BIO.DE. The ticker symbol is used to trade Biotest shares on the stock exchange.
Biotest stock
Biotest Peer Group
Biotest Ticker
Biotest FIGI
All fundamentals and in-depth analysis of Biotest
Our stock analysis for Biotest stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.